| 主題 |
日期
(日/月/年) |
| 這連結會以新視窗打開Ilaris (canakinumab): Assessing the potential risk of drug reaction with eosinophilia and systemic symptoms (Letter to Healthcare Professionals) (只備英文版) |
20-12-2024 |
| 這連結會以新視窗打開一宗本地感染登革熱個案 (只備英文版) |
29-11-2024 |
| 這連結會以新視窗打開Promethazine hydrochloride (Phenergan) not to be used in children under 6 (Letter to Healthcare Professionals) (只備英文版) |
20-11-2024 |
| 這連結會以新視窗打開Tegretol Oral Suspension 2%: Update to the posology, method of administration, and limitation of use in neonates (Letter to Healthcare Professionals) (只備英文版) |
13-11-2024 |
| 這連結會以新視窗打開Olanzapine: Assessing the potential risks of syndrome of inappropriate secretion of antidiuretic hormone and hyponatremia (Letter to Healthcare Professionals) (只備英文版) |
1-11-2024 |
| 這連結會以新視窗打開Gavreto® (pralsetinib): New warning and precaution of severe and fatal infections (Letter to Healthcare Professionals) (只備英文版) |
30-10-2024 |
| 這連結會以新視窗打開提高警覺預防手足口病 (只備英文版) |
9-10-2024 |
| 這連結會以新視窗打開 在假期間提高警覺預防登革熱 (只備英文版) |
2-10-2024 |
| 這連結會以新視窗打開Summary Safety Review - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the potential risks of prolonged or incident diabetic ketoacidosis despite stopping treatment in adult patients with type 2 diabetes (Letter to Healthcare Professionals) (只備英文版) |
27-9-2024 |
| 這連結會以新視窗打開Plaquenil® (Hydroxychloroquine sulfate): Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms (Letter to Healthcare Professionals) (只備英文版) |
20-9-2024 |
| 這連結會以新視窗打開Vigilance against Invasive Group B Streptococcus Infection (只備英文版) |
14-9-2024 |
| 這連結會以新視窗打開Lunsumio (mosunetuzumab): New important identified risk of Hemophagocytic Lymphohistiocytosis (Letter to Healthcare Professionals) (只備英文版) |
13-9-2024 |
| 這連結會以新視窗打開EMA recommends measures to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate (Letter to Healthcare Professionals) (只備英文版) |
9-9-2024 |
| 這連結會以新視窗打開一宗本地感染登革熱個案 (只備英文版) |
17-8-2024 |
| 這連結會以新視窗打開世界衞生組織宣布猴痘疫情為國際關注的突發公共衞生事件 (只備英文版) |
15-8-2024 |
| 這連結會以新視窗打開Azithromycin and rare risk of cardiovascular death (Letter to Healthcare Professionals) (只備英文版) |
2-8-2024 |
| 這連結會以新視窗打開EMA advises about risks of using weight loss medicine Mysimba with opioids (Letter to Healthcare Professionals) (只備英文版) |
29-7-2024 |
| 這連結會以新視窗打開Thematic Report on Iron Status (Population Health Survey 2020-22) (只備英文版) |
16-7-2024 |
| 這連結會以新視窗打開New recommendations for GLP-1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation (Letter to Healthcare Professionals) (只備英文版) |
15-7-2024 |
| 這連結會以新視窗打開Nexavar (sorafenib): Assessing the potential risk of tumour lysis syndrome (Letter to Healthcare Professionals) (只備英文版) |
28-6-2024 |
| 這連結會以新視窗打開Warfarin: be alert to the risk of drug interactions with tramadol (Letter to Healthcare Professionals) (只備英文版) |
21-6-2024 |
| 這連結會以新視窗打開一宗可能在本地感染的登革熱個案 (只備英文版) |
19-6-2024 |
| 這連結會以新視窗打開CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin (Letter to Healthcare Professionals) (只備英文版) |
17-6-2024 |
| 這連結會以新視窗打開 呼籲就百日咳個案增加提高警覺 (只備英文版) |
24-5-2024 |
| 這連結會以新視窗打開本地季節性流感最新情況 (只備英文版) |
2-5-2024 |
|
這連結會以新視窗打開CHMP recommended new contraindications on the co-administration of Reyataz (Atazanavir) with encorafenib and ivosidenib, and with carbamazepine, phenobarbital, and phenytoin (Letter to Healthcare Professionals) (只備英文版) |
29-4-2024 |
| 這連結會以新視窗打開今年首宗本地感染的登革熱個案 (只備英文版) |
26-4-2024 |
| 這連結會以新視窗打開Vigilance against B virus infection and addition of the infection to the list of “Other communicable diseases of topical public health concern” (只備英文版) |
5-4-2024 |
| 這連結會以新視窗打開Ezetrol (ezetimibe) and the risks of drug-induced liver injury and severe cutaneous adverse reactions (Letter to Healthcare Professionals) (只備英文版) |
28-3-2024 |
|
這連結會以新視窗打開Amiodarone: Assessing the potential risk of primary graft dysfunction following heart transplantation (Letter to Healthcare Professionals) (只備英文版)
|
28-3-2024 |
| 這連結會以新視窗打開Ibrance (palbociclib): Assessing the potential risk of venous thromboembolism (Letter to Healthcare Professionals) (只備英文版) |
28-3-2024 |
| 這連結會以新視窗打開Updated warnings of faricimab (Vabysmo): retinal vasculitis risk (Letter to Healthcare Professionals) (只備英文版) |
21-3-2024 |
| 這連結會以新視窗打開Colistin (colistimethate sodium): Assessing the potential risk of pseudo-Bartter syndrome (Letter to Healthcare Professionals)(只備英文版) |
1-3-2024 |
| 這連結會以新視窗打開Vigilance against upsurge of measles(只備英文版) |
29-2-2024 |
| 這連結會以新視窗打開Vigilance against ceftriaxone reduced susceptible Neisseria gonorrhoeae infection |
30-1-2024 |
| 這連結會以新視窗打開Safety-related information for the product Mifegyne (Letter to Healthcare Professionals) (只備英文版) |
25-1-2024 |
| 這連結會以新視窗打開含mifepristone成分藥品安全資訊 (Letter to Healthcare Professionals) |
24-1-2024 |
| 這連結會以新視窗打開BCMA- and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapies: risk of T cell malignancies (Letter to Healthcare Professionals) (只備英文版) |
24-1-2024 |
| 這連結會以新視窗打開Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate in the United Kingdom (Letter to Healthcare Professionals) (只備英文版) |
23-1-2024 |
| 這連結會以新視窗打開Arrival of the 2023/24 Winter Influenza Season in Hong Kong |
11-1-2024 |